TOP

Press Releases

You can read it in the journals and newspapers, or you can read it here first. Please check back frequently to see where the future is headed, compliments of Sequenom.

August 2014

Aug 5, 2014 SAN DIEGO, Aug. 5, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 2014 Wedbush Securities Life Sciences Management Access Conference at Le Parker Meridien in New York, NY on August 12-13, 2014. William Welch, President and Chief Operating Officer, will present on Tuesday, August 12, beginning at 4:15 p.m. ET to provide an overview of and update on the... Read more

July 2014

Jul 29, 2014 SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company that provides innovative genetic analysis solutions, and Mayo Medical Laboratories (MML), the third-largest provider of esoteric laboratory services in the United States, have announced a license agreement for noninvasive prenatal testing patents and applications. "We have great appreciation for Mayo Clinic's commitment to research, innovation, and patient care, and we welcome the... Read more
62% Revenue Growth as Reimbursement and Testing Volumes Improve Jul 29, 2014 SAN DIEGO, July 29, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $39.8 million for the second quarter of 2014, an increase of 62% compared to revenues of $24.5 million for the second quarter of 2013. The Bioscience business segment, which was sold on May 30, 2014, has been accounted for as a discontinued... Read more
Jul 22, 2014 SAN DIEGO, July 22, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin reporting on the presence of three additional clinically relevant subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS) for its MaterniT21™ PLUS laboratory-developed test. The microdeletions added include 11q deletion (Jacobsen... Read more
New Data Supporting the Clinical Validity of Sequenom Laboratories' Noninvasive Prenatal Tests Presented at the 18th International Conference on Prenatal Diagnosis and Therapy Jul 21, 2014 SAN DIEGO, July 21, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch  the VisibiliT™ laboratory-developed test in international markets. The... Read more
Jul 15, 2014 SAN DIEGO, July 15, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced it will report financial results for the second quarter of 2014 after closing of the NASDAQ Global Market on Tuesday, July 29, 2014. A conference call hosted by William Welch, Chief Executive Officer, and other members of senior management will take place on the same day at 5:00 p.m. EDT (2:00 p.m. PDT) and will be webcast... Read more

Pages